CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...
The device is established in Europe, where the company said it has a 60% market share, but will be the first product of its type available in the U.S.